marketcaparena
Search

    BSX

    BOSTON SCIENTIFIC CORP

    Company overview

    Market capitalization
    $63.93B
    Employees
    59,000
    Latest publication
    2026-09-29
    About BOSTON SCIENTIFIC CORP

    Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

    Company website

    Financial statements

    Income YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Total Revenue10,646,000,000USD
    Cost Of Revenue3,184,000,000USD
    Gross Profit7,462,000,000USD
    Research Development1,069,000,000USD
    Selling General Administrative3,583,000,000USD
    Other Operating Expenses-11,000,000USD
    Total Operating Expenses5,183,000,000USD
    Operating Income2,279,000,000USD
    Total Other Income Expense Net-57,000,000USD
    Interest Expense186,000,000USD
    Litigation Settlement Expense76,000,000USD
    Depreciation And Amortization466,000,000USD
    Income Before Tax2,222,000,000USD
    Income Tax Expense-21,000,000USD
    Net Income2,243,000,000USD
    Minority Interest-4,000,000USD
    Net Income Applicable To Common Shares2,247,000,000USD
    SourceDisclosureDeterministicFinal

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue5,442,000,000USD5,203,000,000USD5,286,000,000USD5,065,000,000USD5,061,000,000USD4,663,000,000USD4,561,000,000USD4,209,000,000USD
    Cost Of Revenue1,594,000,000USD1,590,000,000USD1,348,000,000USD1,523,000,000USD1,637,000,000USD1,713,000,000USD1,890,000,000USD1,561,000,000USD
    Gross Profit3,848,000,000USD3,613,000,000USD3,937,000,000USD3,542,000,000USD3,424,000,000USD2,950,000,000USD2,671,000,000USD2,648,000,000USD
    Research Development554,000,000USD516,000,000USD569,000,000USD514,000,000USD526,000,000USD443,000,000USD460,000,000USD407,000,000USD
    Selling General Administrative1,803,000,000USD1,781,000,000USD1,834,000,000USD1,741,000,000USD1,716,000,000USD1,597,000,000USD1,612,000,000USD1,562,000,000USD
    Other Operating Expenses4,000,000USD———————
    Total Operating Expenses2,670,000,000USD2,541,000,000USD2,731,000,000USD2,492,000,000USD2,605,000,000USD2,054,000,000USD2,082,000,000USD1,974,000,000USD
    Operating Income1,178,000,000USD1,072,000,000USD1,206,000,000USD1,050,000,000USD819,000,000USD896,000,000USD589,000,000USD674,000,000USD
    Total Other Income Expense Net-118,000,000USD90,000,000USD-506,000,000USD-111,000,000USD122,000,000USD-91,000,000USD-4,000,000USD-6,000,000USD
    Interest Expense96,000,000USD90,000,000USD90,000,000USD87,000,000USD90,000,000USD87,000,000USD139,000,000USD83,000,000USD
    Litigation Settlement Expense76,000,000USD———————
    Depreciation And Amortization233,000,000USD351,000,000USD365,000,000USD342,000,000USD336,000,000USD325,000,000USD348,000,000USD307,000,000USD
    Income Before Tax1,060,000,000USD1,162,000,000USD700,000,000USD939,000,000USD941,000,000USD805,000,000USD585,000,000USD668,000,000USD
    Income Tax Expense155,000,000USD-176,000,000USD31,000,000USD183,000,000USD146,000,000USD133,000,000USD23,000,000USD200,000,000USD
    Net Income905,000,000USD1,337,000,000USD668,000,000USD755,000,000USD793,000,000USD674,000,000USD566,000,000USD469,000,000USD
    Minority Interest-2,000,000USD2,000,000USD2,000,000USD0USD2,000,000USD2,000,000USD4,000,000USD0USD
    Net Income Applicable To Common Shares907,000,000USD—672,000,000USD755,000,000USD797,000,000USD674,000,000USD565,000,000USD469,000,000USD
    Unclassified Operating Expenses—244,000,000USD328,000,000USD237,000,000USD363,000,000USD———
    Net Interest Income—-90,000,000USD-61,000,000USD-87,000,000USD-90,000,000USD-82,000,000USD27,000,000USD-79,000,000USD
    Tax Provision—-176,000,000USD30,000,000USD183,000,000USD146,000,000USD133,000,000USD23,000,000USD200,000,000USD
    Net Income From Continuing Ops—1,338,000,000USD670,000,000USD756,000,000USD795,000,000USD672,000,000USD562,000,000USD469,000,000USD
    Ebit—1,252,000,000USD790,000,000USD1,026,000,000USD1,031,000,000USD892,000,000USD723,000,000USD751,000,000USD
    Ebitda—1,603,000,000USD1,155,000,000USD1,368,000,000USD1,367,000,000USD1,217,000,000USD1,071,000,000USD1,058,000,000USD
    Reconciled Depreciation—351,000,000USD365,000,000USD342,000,000USD336,000,000USD325,000,000USD348,000,000USD306,000,000USD
    Interest Income——90,000,000USD99,000,000USD90,000,000USD82,000,000USD164,000,000USD83,000,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Revenue20,074,000,000USD16,747,000,000USD14,240,000,000USD12,682,000,000USD11,888,000,000USD9,913,000,000USD10,735,000,000USD9,823,000,000USD
    Cost Of Revenue6,221,000,000USD6,480,000,000USD5,409,000,000USD4,968,000,000USD4,427,000,000USD4,337,000,000USD3,856,000,000USD3,346,000,000USD
    Gross Profit13,853,000,000USD10,267,000,000USD8,831,000,000USD7,714,000,000USD7,461,000,000USD5,576,000,000USD6,879,000,000USD6,477,000,000USD
    Research Development2,052,000,000USD1,615,000,000USD1,414,000,000USD1,323,000,000USD1,204,000,000USD1,143,000,000USD1,174,000,000USD1,113,000,000USD
    Selling General Administrative6,887,000,000USD5,984,000,000USD4,974,000,000USD4,520,000,000USD4,359,000,000USD3,787,000,000USD3,941,000,000USD3,569,000,000USD
    Unclassified Operating Expenses943,000,000USD—262,000,000USD———52,000,000USD58,000,000USD
    Total Operating Expenses9,882,000,000USD7,632,000,000USD6,650,000,000USD5,890,000,000USD5,539,000,000USD4,975,000,000USD5,167,000,000USD4,740,000,000USD
    Operating Income3,971,000,000USD2,635,000,000USD2,181,000,000USD1,824,000,000USD1,922,000,000USD601,000,000USD1,712,000,000USD1,737,000,000USD
    Interest Income349,000,000USD107,000,000USD22,000,000USD470,000,000USD341,000,000USD361,000,000USD30,000,000USD3,000,000USD
    Interest Expense349,000,000USD387,000,000USD272,000,000USD464,000,000USD349,000,000USD468,000,000USD513,000,000USD269,000,000USD
    Net Interest Income-320,000,000USD-198,000,000USD-254,000,000USD-470,000,000USD-341,000,000USD-361,000,000USD-443,000,000USD-238,000,000USD
    Income Before Tax3,385,000,000USD2,282,000,000USD1,985,000,000USD1,141,000,000USD1,076,000,000USD-79,000,000USD687,000,000USD1,422,000,000USD
    Income Tax Expense493,000,000USD436,000,000USD393,000,000USD443,000,000USD36,000,000USD2,000,000USD-4,013,000,000USD-249,000,000USD
    Tax Provision493,000,000USD436,000,000USD647,000,000USD443,000,000USD36,000,000USD2,000,000USD-4,013,000,000USD-249,000,000USD
    Net Income2,886,000,000USD1,854,000,000USD1,593,000,000USD698,000,000USD1,040,000,000USD-82,000,000USD4,700,000,000USD1,671,000,000USD
    Net Income From Continuing Ops2,892,000,000USD1,846,000,000USD1,228,000,000USD698,000,000USD1,041,000,000USD-81,000,000USD4,700,000,000USD1,671,000,000USD
    Ebit3,734,000,000USD2,669,000,000USD2,257,000,000USD1,605,000,000USD1,425,000,000USD389,000,000USD1,200,000,000USD1,691,000,000USD
    Ebitda5,102,000,000USD3,938,000,000USD3,453,000,000USD2,741,000,000USD2,518,000,000USD1,511,000,000USD2,210,000,000USD2,585,000,000USD
    Depreciation And Amortization1,368,000,000USD1,269,000,000USD1,196,000,000USD1,136,000,000USD1,093,000,000USD1,122,000,000USD1,010,000,000USD894,000,000USD
    Reconciled Depreciation1,368,000,000USD1,269,000,000USD1,177,000,000USD803,000,000USD741,000,000USD1,123,000,000USD1,011,000,000USD894,000,000USD
    Total Other Income Expense Net-586,000,000USD-353,000,000USD-196,000,000USD-683,000,000USD-846,000,000USD-680,000,000USD-1,025,000,000USD-315,000,000USD
    Minority Interest6,000,000USD8,000,000USD1,000,000USD0USD0USD———
    Net Income Applicable To Common Shares2,898,000,000USD1,853,000,000USD1,570,000,000USD642,000,000USD986,000,000USD-115,000,000USD4,700,000,000USD1,671,000,000USD
    Non Operating Income Net Other———-38,000,000USD218,000,000USD362,000,000USD-358,000,000USD156,000,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets45,216,000,000USD44,351,000,000USD43,673,000,000USD42,707,000,000USD41,559,000,000USD40,140,000,000USD39,395,000,000USD38,078,000,000USD
    Cash And Equivalents539,000,000USD—1,965,000,000USD1,275,000,000USD534,000,000USD725,000,000USD414,000,000USD2,502,000,000USD
    Long Term Investments2,245,000,000USD——643,000,000USD626,000,000USD655,000,000USD555,000,000USD532,000,000USD
    Total Current Assets7,972,000,000USD8,684,000,000USD8,794,000,000USD8,035,000,000USD7,121,000,000USD7,335,000,000USD6,920,000,000USD8,761,000,000USD
    Other Current Assets760,000,000USD1,016,000,000USD879,000,000USD1,011,000,000USD911,000,000USD1,050,000,000USD1,138,000,000USD1,005,000,000USD
    Other Non Current Assets1,405,000,000USD———————
    Total Liabilities20,044,000,000USD———————
    Total Current Liabilities6,428,000,000USD4,571,000,000USD5,439,000,000USD5,328,000,000USD5,190,000,000USD5,058,000,000USD6,399,000,000USD5,910,000,000USD
    Other Current Liabilities732,000,000USD———————
    Other Non Current Liabilities2,480,000,000USD———————
    Total Stockholder Equity24,930,000,000USD25,864,000,000USD24,233,000,000USD23,395,000,000USD22,418,000,000USD22,212,000,000USD21,770,000,000USD20,708,000,000USD
    Total Equity Including Noncontrolling Interest25,172,000,000USD———————
    Short Long Term Debt12,624,000,000USD41,000,000USD299,000,000USD483,000,000USD480,000,000USD777,000,000USD1,778,000,000USD1,652,000,000USD
    Long Term Debt10,915,000,000USD10,864,000,000USD11,137,000,000USD10,993,000,000USD10,981,000,000USD10,406,000,000USD8,842,000,000USD9,229,000,000USD
    Net Receivables3,049,000,000USD3,027,000,000USD2,926,000,000USD2,828,000,000USD2,815,000,000USD2,693,000,000USD2,558,000,000USD2,501,000,000USD
    Inventory3,235,000,000USD3,117,000,000USD2,944,000,000USD2,921,000,000USD2,861,000,000USD2,867,000,000USD2,810,000,000USD2,753,000,000USD
    Property Plant Equipment Net4,679,000,000USD4,610,000,000USD4,501,000,000USD4,289,000,000USD3,952,000,000USD3,837,000,000USD3,744,000,000USD3,498,000,000USD
    Goodwill18,640,000,000USD———————
    Intangible Assets6,918,000,000USD7,060,000,000USD7,019,000,000USD7,161,000,000USD7,259,000,000USD6,565,000,000USD6,684,000,000USD5,754,000,000USD
    Accounts Payable1,231,000,000USD1,141,000,000USD1,144,000,000USD1,002,000,000USD962,000,000USD1,004,000,000USD960,000,000USD907,000,000USD
    Short Term Debt1,709,000,000USD41,000,000USD389,000,000USD483,000,000USD480,000,000USD777,000,000USD1,778,000,000USD1,652,000,000USD
    Common Stock17,000,000USD17,000,000USD17,000,000USD17,000,000USD17,000,000USD17,000,000USD17,000,000USD17,000,000USD
    Retained Earnings7,818,000,000USD6,912,000,000USD5,571,000,000USD4,899,000,000USD4,144,000,000USD3,347,000,000USD2,673,000,000USD2,107,000,000USD
    Accumulated Other Comprehensive Income-304,000,000USD-398,000,000USD-610,000,000USD-689,000,000USD-722,000,000USD-28,000,000USD275,000,000USD-128,000,000USD
    Total Liab—18,247,000,000USD19,201,000,000USD19,077,000,000USD18,906,000,000USD17,694,000,000USD17,392,000,000USD17,122,000,000USD
    Other Current Liab—3,389,000,000USD3,294,000,000USD3,360,000,000USD3,262,000,000USD2,677,000,000USD3,087,000,000USD2,729,000,000USD
    Capital Stock—17,000,000USD17,000,000USD17,000,000USD17,000,000USD17,000,000USD17,000,000USD17,000,000USD
    Good Will—18,536,000,000USD18,282,000,000USD18,214,000,000USD18,076,000,000USD17,340,000,000USD17,089,000,000USD15,033,000,000USD
    Cash—1,524,000,000USD2,045,000,000USD1,275,000,000USD534,000,000USD725,000,000USD414,000,000USD2,502,000,000USD
    Cash And Short Term Investments—1,524,000,000USD2,045,000,000USD1,275,000,000USD534,000,000USD725,000,000USD414,000,000USD2,502,000,000USD
    Net Debt—9,505,000,000USD10,373,000,000USD10,771,000,000USD11,493,000,000USD10,983,000,000USD10,733,000,000USD8,756,000,000USD
    Short Long Term Debt Total—11,029,000,000USD12,418,000,000USD12,046,000,000USD12,027,000,000USD11,708,000,000USD11,147,000,000USD11,258,000,000USD
    Property Plant Equipment Gross—7,737,000,000USD7,645,000,000USD8,150,000,000USD7,735,000,000USD7,479,000,000USD7,277,000,000USD7,120,000,000USD
    Common Stock Shares Outstanding—1,495,000,000shares1,495,800,000shares1,495,500,000shares1,493,300,000shares1,493,100,000shares1,490,200,000shares1,487,400,000shares
    Non Current Assets Total—35,667,000,000USD34,879,000,000USD34,671,000,000USD34,437,000,000USD32,805,000,000USD32,476,000,000USD29,317,000,000USD
    Non Current Liabilities Total—13,676,000,000USD13,762,000,000USD13,749,000,000USD13,716,000,000USD12,636,000,000USD10,993,000,000USD11,212,000,000USD
    Non Current Liabilities Other—2,469,000,000USD2,405,000,000USD1,028,000,000USD1,038,000,000USD671,000,000USD634,000,000USD652,000,000USD
    Non Currrent Assets Other—573,000,000USD559,000,000USD546,000,000USD746,000,000USD732,000,000USD749,000,000USD684,000,000USD
    Net Working Capital—4,113,000,000USD3,355,000,000USD2,707,000,000USD1,931,000,000USD2,277,000,000USD521,000,000USD2,851,000,000USD
    Unclassified Non Current Assets—4,888,000,000USD-559,000,000USD3,817,000,000USD3,777,000,000USD-731,000,000USD3,655,000,000USD-684,000,000USD
    Unclassified Non Current Liabilities—343,000,000USD220,000,000USD1,728,000,000USD1,697,000,000USD1,559,000,000USD1,517,000,000USD1,331,000,000USD
    Unclassified Equity—19,316,000,000USD19,238,000,000USD19,151,000,000USD18,962,000,000USD18,859,000,000USD18,788,000,000USD18,695,000,000USD
    Other Assets——5,077,000,000USD1,000,000USD1,000,000USD4,407,000,000USD-1,000,000USD4,500,000,000USD
    Current Deferred Revenue——313,000,000USD309,000,000USD313,000,000USD306,000,000USD306,000,000USD290,000,000USD
    Unclassified Current Liabilities———-309,000,000USD-307,000,000USD-483,000,000USD-1,510,000,000USD-1,320,000,000USD
    Short Term Investments———————117,000,000USD
    Unclassified Current Assets———————-117,000,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets43,673,000,000USD39,395,000,000USD35,136,000,000USD32,470,000,000USD32,230,000,000USD30,778,000,000USD30,565,000,000USD20,998,000,000USD
    Intangible Assets7,019,000,000USD6,684,000,000USD6,003,000,000USD5,903,000,000USD6,120,000,000USD5,916,000,000USD7,886,000,000USD6,372,000,000USD
    Other Current Assets879,000,000USD1,138,000,000USD937,000,000USD995,000,000USD1,004,000,000USD2,078,000,000USD1,075,000,000USD922,000,000USD
    Total Liab19,201,000,000USD17,392,000,000USD15,606,000,000USD14,896,000,000USD15,607,000,000USD15,451,000,000USD16,688,000,000USD12,273,000,000USD
    Total Stockholder Equity24,233,000,000USD21,770,000,000USD19,282,000,000USD17,574,000,000USD16,623,000,000USD15,327,000,000USD13,877,000,000USD8,725,000,000USD
    Other Current Liab3,294,000,000USD3,048,000,000USD2,974,000,000USD2,469,000,000USD2,802,000,000USD2,859,000,000USD2,499,000,000USD2,330,000,000USD
    Common Stock17,000,000USD17,000,000USD17,000,000USD17,000,000USD17,000,000USD17,000,000USD16,000,000USD16,000,000USD
    Capital Stock17,000,000USD17,000,000USD17,000,000USD17,000,000USD17,000,000USD17,000,000USD16,000,000USD16,000,000USD
    Retained Earnings5,571,000,000USD2,673,000,000USD819,000,000USD-750,000,000USD-1,392,000,000USD-2,378,000,000USD-2,253,000,000USD-6,953,000,000USD
    Good Will18,282,000,000USD17,089,000,000USD14,387,000,000USD12,920,000,000USD11,988,000,000USD9,951,000,000USD10,176,000,000USD7,911,000,000USD
    Other Assets5,077,000,000USD-1,000,000USD1,000,000USD-1,000,000USD2,000,000USD3,000,000USD4,599,000,000USD-2,000,000USD
    Cash2,045,000,000USD414,000,000USD865,000,000USD928,000,000USD1,925,000,000USD1,734,000,000USD217,000,000USD146,000,000USD
    Cash And Equivalents1,965,000,000USD414,000,000USD865,000,000USD928,000,000USD1,925,000,000USD1,734,000,000USD217,000,000USD146,000,000USD
    Cash And Short Term Investments2,045,000,000USD414,000,000USD865,000,000USD928,000,000USD1,925,000,000USD1,734,000,000USD217,000,000USD146,000,000USD
    Total Current Assets8,794,000,000USD6,920,000,000USD6,514,000,000USD5,760,000,000USD6,317,000,000USD6,694,000,000USD4,699,000,000USD4,003,000,000USD
    Total Current Liabilities5,439,000,000USD6,399,000,000USD4,933,000,000USD3,803,000,000USD4,274,000,000USD3,681,000,000USD4,866,000,000USD5,260,000,000USD
    Current Deferred Revenue313,000,000USD306,000,000USD266,000,000USD220,000,000USD208,000,000USD138,000,000USD144,000,000USD328,000,000USD
    Net Debt10,373,000,000USD10,733,000,000USD8,627,000,000USD8,354,000,000USD7,526,000,000USD7,805,000,000USD10,060,000,000USD6,884,000,000USD
    Short Term Debt389,000,000USD1,778,000,000USD531,000,000USD20,000,000USD261,000,000USD13,000,000USD1,416,000,000USD2,253,000,000USD
    Short Long Term Debt299,000,000USD1,778,000,000USD531,000,000USD20,000,000USD261,000,000USD13,000,000USD1,416,000,000USD2,253,000,000USD
    Short Long Term Debt Total12,418,000,000USD11,147,000,000USD9,492,000,000USD9,282,000,000USD9,451,000,000USD9,539,000,000USD10,277,000,000USD7,056,000,000USD
    Long Term Debt11,137,000,000USD8,842,000,000USD8,566,000,000USD8,915,000,000USD8,795,000,000USD9,118,000,000USD8,586,000,000USD4,797,000,000USD
    Net Receivables2,926,000,000USD2,558,000,000USD2,228,000,000USD1,970,000,000USD1,778,000,000USD1,531,000,000USD1,828,000,000USD1,608,000,000USD
    Inventory2,944,000,000USD2,810,000,000USD2,484,000,000USD1,867,000,000USD1,610,000,000USD1,351,000,000USD1,579,000,000USD1,166,000,000USD
    Accounts Payable1,144,000,000USD960,000,000USD942,000,000USD862,000,000USD794,000,000USD513,000,000USD542,000,000USD349,000,000USD
    Property Plant Equipment Net4,501,000,000USD3,744,000,000USD3,298,000,000USD2,831,000,000USD2,686,000,000USD2,541,000,000USD2,415,000,000USD1,782,000,000USD
    Property Plant Equipment Gross7,645,000,000USD7,277,000,000USD6,782,000,000USD2,446,000,000USD2,252,000,000USD2,541,000,000USD2,415,000,000USD1,782,000,000USD
    Accumulated Other Comprehensive Income-610,000,000USD275,000,000USD49,000,000USD269,000,000USD263,000,000USD207,000,000USD270,000,000USD33,000,000USD
    Common Stock Shares Outstanding1,494,500,000shares1,485,900,000shares1,463,500,000shares1,439,700,000shares1,433,800,000shares1,416,700,000shares1,410,600,000shares1,401,400,000shares
    Non Current Assets Total34,879,000,000USD32,476,000,000USD28,622,000,000USD26,710,000,000USD25,911,000,000USD24,081,000,000USD25,866,000,000USD16,997,000,000USD
    Non Current Liabilities Total13,762,000,000USD10,993,000,000USD10,673,000,000USD11,093,000,000USD11,333,000,000USD11,770,000,000USD11,822,000,000USD7,013,000,000USD
    Non Current Liabilities Other2,405,000,000USD634,000,000USD625,000,000USD2,035,000,000USD2,220,000,000USD2,309,000,000USD2,635,000,000USD1,882,000,000USD
    Non Currrent Assets Other559,000,000USD749,000,000USD680,000,000USD707,000,000USD563,000,000USD545,000,000USD735,000,000USD932,000,000USD
    Net Working Capital3,355,000,000USD521,000,000USD1,581,000,000USD1,957,000,000USD2,043,000,000USD3,013,000,000USD-167,000,000USD-1,257,000,000USD
    Unclassified Non Current Assets-559,000,000USD3,655,000,000USD3,840,000,000USD3,942,000,000USD4,140,000,000USD4,207,000,000USD-403,000,000USD-424,000,000USD
    Unclassified Non Current Liabilities220,000,000USD1,517,000,000USD1,482,000,000USD-1,832,000,000USD-2,132,000,000USD-2,226,000,000USD-2,948,000,000USD-2,204,000,000USD
    Unclassified Equity19,238,000,000USD18,788,000,000USD18,380,000,000USD20,272,000,000USD19,969,000,000USD19,715,000,000USD17,545,000,000USD17,330,000,000USD
    Long Term Investments—555,000,000USD413,000,000USD407,000,000USD412,000,000USD918,000,000USD458,000,000USD424,000,000USD
    Unclassified Current Liabilities—-1,471,000,000USD-311,000,000USD212,000,000USD-52,000,000USD145,000,000USD-1,151,000,000USD-2,253,000,000USD
    Deferred Long Term Liab———144,000,000USD310,000,000USD330,000,000USD595,000,000USD328,000,000USD
    Other Liab———1,831,000,000USD2,140,000,000USD2,239,000,000USD2,954,000,000USD2,210,000,000USD
    Treasury Stock———-2,251,000,000USD-2,251,000,000USD-2,251,000,000USD-1,717,000,000USD-1,717,000,000USD
    Net Tangible Assets———11,670,000,000USD-1,723,000,000USD9,410,000,000USD-4,185,000,000USD-5,557,000,000USD
    Unclassified Current Assets———————161,000,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Net Income2,243,000,000USD
    Depreciation706,000,000USD
    Stock Based Compensation170,000,000USD
    Deferred Income Tax-334,000,000USD
    Other Non Cash Items-123,000,000USD
    Unclassified Operating Cash Flow1,000,000USD
    Change To Account Receivables-163,000,000USD
    Change To Inventory-310,000,000USD
    Change To Liabilities-278,000,000USD
    Change In Working Capital-841,000,000USD
    Operating Cash Flow1,822,000,000USD
    Capital Expenditures-372,000,000USD
    Net Investments-1,501,000,000USD
    Other Investing Activities43,000,000USD
    Unclassified Investing Cash Flow-717,000,000USD
    Investing Cash Flow-2,547,000,000USD
    Net Debt Issuance1,403,000,000USD
    Common Stock Issuance86,000,000USD
    Net Common Stock Issuance-2,088,000,000USD
    Other Financing Activities-70,000,000USD
    Unclassified Financing Cash Flow-1,000,000USD
    Financing Cash Flow-670,000,000USD
    Effect Of Forex Changes On Cash1,000,000USD
    Change In Cash-1,394,000,000USD
    End Cash Flow753,000,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ2 20242024-06-30 · USDQ1 20242024-03-31 · USD
    Net Income1,341,000,000USD672,000,000USD755,000,000USD795,000,000USD672,000,000USD562,000,000USD324,000,000USD493,000,000USD
    Depreciation351,000,000USD365,000,000USD342,000,000USD336,000,000USD325,000,000USD348,000,000USD311,000,000USD304,000,000USD
    Stock Based Compensation83,000,000USD71,000,000USD79,000,000USD75,000,000USD74,000,000USD69,000,000USD195,000,000USD63,000,000USD
    Other Non Cash Items-78,000,000USD194,000,000USD54,000,000USD-63,000,000USD107,000,000USD233,000,000USD202,000,000USD16,000,000USD
    Change To Account Receivables-117,000,000USD-98,000,000USD-32,000,000USD-32,000,000USD-107,000,000USD52,000,000USD-114,000,000USD-114,000,000USD
    Change To Inventory-177,000,000USD-50,000,000USD-94,000,000USD65,000,000USD-109,000,000USD46,000,000USD-95,000,000USD-124,000,000USD
    Change In Working Capital-915,000,000USD155,000,000USD44,000,000USD233,000,000USD-678,000,000USD324,000,000USD-209,000,000USD-743,000,000USD
    Total Cash From Operating Activities348,000,000USD1,364,000,000USD1,343,000,000USD1,286,000,000USD541,000,000USD1,456,000,000USD813,000,000USD164,000,000USD
    Capital Expenditures-177,000,000USD-351,000,000USD-181,000,000USD-190,000,000USD-187,000,000USD-293,000,000USD-155,000,000USD-245,000,000USD
    Free Cash Flow171,000,000USD1,013,000,000USD1,162,000,000USD1,096,000,000USD354,000,000USD1,163,000,000USD658,000,000USD-81,000,000USD
    Total Cashflows From Investing Activities-591,000,000USD-512,000,000USD-502,000,000USD-1,126,000,000USD-500,000,000USD-3,704,000,000USD-271,000,000USD-285,000,000USD
    Net Borrowings-259,000,000USD-209,000,000USD-215,000,000USD-314,000,000USD247,000,000USD189,000,000USD——
    Total Cash From Financing Activities-260,000,000USD-184,000,000USD-104,000,000USD-340,000,000USD233,000,000USD214,000,000USD24,000,000USD1,569,000,000USD
    Change In Cash-521,000,000USD672,000,000USD730,000,000USD-178,000,000USD313,000,000USD-2,043,000,000USD566,000,000USD1,441,000,000USD
    Begin Period Cash Flow2,045,000,000USD1,373,000,000USD643,000,000USD919,000,000USD606,000,000USD2,649,000,000USD2,422,000,000USD1,055,000,000USD
    End Period Cash Flow1,524,000,000USD2,045,000,000USD1,373,000,000USD741,000,000USD919,000,000USD606,000,000USD2,988,000,000USD2,496,000,000USD
    Other Cashflows From Investing Activities48,000,000USD2,000,000USD-65,000,000USD40,000,000USD-74,000,000USD-9,000,000USD5,000,000USD7,000,000USD
    Other Cashflows From Financing Activities-82,000,000USD201,000,000USD-200,000,000USD-58,000,000USD-129,000,000USD-3,000,000USD-2,000,000USD-127,000,000USD
    Unclassified Operating Cash Flow-434,000,000USD-93,000,000USD69,000,000USD-90,000,000USD41,000,000USD-80,000,000USD-10,000,000USD31,000,000USD
    Unclassified Investing Cash Flow-462,000,000USD-163,000,000USD-256,000,000USD150,000,000USD261,000,000USD302,000,000USD150,000,000USD238,000,000USD
    Unclassified Financing Cash Flow81,000,000USD-458,000,000USD49,000,000USD-115,000,000USD—-202,000,000USD26,000,000USD1,616,000,000USD
    Sale Purchase Of Stock—282,000,000USD262,000,000USD147,000,000USD115,000,000USD230,000,000USD—80,000,000USD
    Investments——0USD-1,126,000,000USD-500,000,000USD-3,704,000,000USD-271,000,000USD-285,000,000USD
    Dividends Paid—————0USD0USD0USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income2,892,000,000USD1,846,000,000USD1,592,000,000USD698,000,000USD1,041,000,000USD-82,000,000USD4,700,000,000USD1,671,000,000USD
    Depreciation1,368,000,000USD1,269,000,000USD1,196,000,000USD1,136,000,000USD1,093,000,000USD1,123,000,000USD1,011,000,000USD894,000,000USD
    Stock Based Compensation299,000,000USD266,000,000USD233,000,000USD220,000,000USD194,000,000USD170,000,000USD157,000,000USD140,000,000USD
    Other Non Cash Items223,000,000USD586,000,000USD253,000,000USD540,000,000USD17,000,000USD337,000,000USD551,000,000USD-148,000,000USD
    Change To Account Receivables-269,000,000USD-351,000,000USD-238,000,000USD-220,000,000USD-279,000,000USD335,000,000USD-130,000,000USD-110,000,000USD
    Change To Inventory-188,000,000USD-228,000,000USD-660,000,000USD-321,000,000USD-346,000,000USD-65,000,000USD-290,000,000USD-83,000,000USD
    Change In Working Capital-246,000,000USD-462,000,000USD-770,000,000USD-1,005,000,000USD-351,000,000USD42,000,000USD-282,000,000USD-2,160,000,000USD
    Total Cash From Operating Activities4,534,000,000USD3,435,000,000USD2,503,000,000USD1,526,000,000USD1,870,000,000USD1,508,000,000USD1,836,000,000USD310,000,000USD
    Capital Expenditures-876,000,000USD-790,000,000USD-800,000,000USD-612,000,000USD-554,000,000USD-376,000,000USD-461,000,000USD-316,000,000USD
    Free Cash Flow3,658,000,000USD2,645,000,000USD1,703,000,000USD914,000,000USD1,316,000,000USD1,132,000,000USD1,375,000,000USD-6,000,000USD
    Total Cashflows From Investing Activities-2,640,000,000USD-5,687,000,000USD-2,574,000,000USD-2,011,000,000USD-1,597,000,000USD-411,000,000USD-5,041,000,000USD-1,921,000,000USD
    Net Borrowings-491,000,000USD1,827,000,000USD-4,000,000USD-165,000,000USD-165,000,000USD-999,000,000USD2,794,000,000USD1,405,000,000USD
    Total Cash From Financing Activities-395,000,000USD1,814,000,000USD5,000,000USD-548,000,000USD-95,000,000USD293,000,000USD2,973,000,000USD1,432,000,000USD
    Sale Purchase Of Stock282,000,000USD230,000,000USD182,000,000USD136,000,000USD110,000,000USD-535,000,000USD123,000,000USD101,000,000USD
    Change In Cash1,541,000,000USD-449,000,000USD-82,000,000USD-1,042,000,000USD173,000,000USD1,388,000,000USD-222,000,000USD-190,000,000USD
    Begin Period Cash Flow606,000,000USD1,055,000,000USD1,077,000,000USD2,168,000,000USD1,995,000,000USD607,000,000USD829,000,000USD1,017,000,000USD
    End Period Cash Flow2,147,000,000USD606,000,000USD995,000,000USD1,126,000,000USD2,168,000,000USD1,995,000,000USD607,000,000USD829,000,000USD
    Other Cashflows From Investing Activities-171,000,000USD-257,000,000USD-52,000,000USD-1,423,000,000USD-1,057,000,000USD111,000,000USD1,000,000USD1,000,000USD
    Other Cashflows From Financing Activities-186,000,000USD-243,000,000USD-145,000,000USD2,806,000,000USD-150,000,000USD6,724,000,000USD56,000,000USD-74,000,000USD
    Unclassified Investing Cash Flow-1,593,000,000USD1,047,000,000USD—-32,000,000USD——-4,233,000,000USD-1,434,000,000USD
    Investments—-5,687,000,000USD-1,704,000,000USD56,000,000USD15,000,000USD-146,000,000USD-348,000,000USD-172,000,000USD
    Dividends Paid—0USD-28,000,000USD-55,000,000USD-55,000,000USD-28,000,000USD-28,000,000USD-28,000,000USD
    Unclassified Operating Cash Flow—-70,000,000USD—-63,000,000USD-124,000,000USD-82,000,000USD-4,301,000,000USD-87,000,000USD
    Change To Liabilities———-255,000,000USD408,000,000USD-28,000,000USD93,000,000USD-1,795,000,000USD
    Issuance Of Capital Stock———0USD0USD1,950,000,000USD123,000,000USD101,000,000USD
    Cash And Cash Equivalents Changes———-1,033,000,000USD178,000,000USD1,390,000,000USD-222,000,000USD-187,000,000USD
    Unclassified Financing Cash Flow———-3,270,000,000USD165,000,000USD-4,869,000,000USD—28,000,000USD
    Exchange Rate Changes——————10,000,000USD-8,000,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30GeographyInternational2,017,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30GeographyUnited States3,426,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductCardiac Rhythm Management585,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductElectrophysiology EP916,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductGlobal Endoscopy Endo Reporting Unit793,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductGlobal Neuromodulation Nm Reporting Unit341,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductGlobal Urologyand Pelvic Health Reporting Unit684,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductInterventional Cardiology Therapies1,333,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductInterventional Oncology And Embolization283,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductWatchman507,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30SegmentCardiovascular3,624,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30SegmentMedsurg1,818,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31GeographyInternational1,920,000,000USD0000885725-26-000033
    Q1 2026Quarterly · 2026-03-31GeographyUnited States3,284,000,000USD0000885725-26-000033
    Q1 2026Quarterly · 2026-03-31ProductCardiac Rhythm Management578,000,000USD0000885725-26-000033
    Q1 2026Quarterly · 2026-03-31ProductElectrophysiology EP905,000,000USD0000885725-26-000033
    Q1 2026Quarterly · 2026-03-31ProductGlobal Endoscopy Endo Reporting Unit736,000,000USD0000885725-26-000033
    Q1 2026Quarterly · 2026-03-31ProductGlobal Neuromodulation Nm Reporting Unit318,000,000USD0000885725-26-000033
    Q1 2026Quarterly · 2026-03-31ProductGlobal Urologyand Pelvic Health Reporting Unit646,000,000USD0000885725-26-000033
    Q1 2026Quarterly · 2026-03-31ProductInterventional Cardiology Therapies1,244,000,000USD0000885725-26-000033
    Q1 2026Quarterly · 2026-03-31ProductInterventional Oncology And Embolization268,000,000USD0000885725-26-000033
    Q1 2026Quarterly · 2026-03-31ProductWatchman506,000,000USD0000885725-26-000033
    Q1 2026Quarterly · 2026-03-31SegmentCardiovascular3,503,000,000USD0000885725-26-000033
    Q1 2026Quarterly · 2026-03-31SegmentMedsurg1,701,000,000USD0000885725-26-000033
    Q4 2025Quarterly · 2025-12-31SegmentCardiovascular3,477,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31SegmentMedsurg1,809,000,000USDLegacy provider
    FY 2025Yearly · 2025-12-31ProductCardiac Rhythm Management2,332,000,000USD0000885725-26-000010
    FY 2025Yearly · 2025-12-31ProductElectrophysiology EP3,325,000,000USD0000885725-26-000010
    FY 2025Yearly · 2025-12-31ProductGlobal Endoscopy Endo Reporting Unit2,916,000,000USD0000885725-26-000010
    FY 2025Yearly · 2025-12-31ProductGlobal Neuromodulation Nm Reporting Unit1,199,000,000USD0000885725-26-000010
    FY 2025Yearly · 2025-12-31ProductGlobal Urologyand Pelvic Health Reporting Unit2,709,000,000USD0000885725-26-000010
    FY 2025Yearly · 2025-12-31ProductInterventional Cardiology Vascular Therapies4,639,000,000USD0000885725-26-000010
    FY 2025Yearly · 2025-12-31ProductInterventional Oncology Embolization996,000,000USD0000885725-26-000010
    FY 2025Yearly · 2025-12-31ProductWatchman1,958,000,000USD0000885725-26-000010
    FY 2025Yearly · 2025-12-31SegmentCardiovascular13,250,000,000USD0000885725-26-000010
    FY 2025Yearly · 2025-12-31SegmentMedsurg6,824,000,000USD0000885725-26-000010
    Q3 2025Quarterly · 2025-09-30ProductGlobal Cardiology Reporting Unit — Cardiac Rhythm Management578,000,000USD0000885725-25-000050
    Q3 2025Quarterly · 2025-09-30ProductGlobal Cardiology Reporting Unit — Electrophysiology EP865,000,000USD0000885725-25-000050
    Q3 2025Quarterly · 2025-09-30ProductGlobal Cardiology Reporting Unit — Watchman512,000,000USD0000885725-25-000050
    Q3 2025Quarterly · 2025-09-30ProductGlobal Endoscopy Endo Reporting Unit747,000,000USD0000885725-25-000050
    Q3 2025Quarterly · 2025-09-30ProductGlobal Neuromodulation Nm Reporting Unit293,000,000USD0000885725-25-000050
    Q3 2025Quarterly · 2025-09-30ProductGlobal Peripheral Interventions Pi Reporting Unit702,000,000USD0000885725-25-000050
    Q3 2025Quarterly · 2025-09-30ProductGlobal Urologyand Pelvic Health Reporting Unit682,000,000USD0000885725-25-000050
    Q3 2025Quarterly · 2025-09-30ProductInterventional Cardiology Therapies686,000,000USD0000885725-25-000050
    Q3 2025Quarterly · 2025-09-30SegmentCardiovascular3,343,000,000USD0000885725-25-000050
    Q3 2025Quarterly · 2025-09-30SegmentMedsurg1,722,000,000USD0000885725-25-000050
    Q2 2025Quarterly · 2025-06-30ProductGlobal Cardiology Reporting Unit — Cardiac Rhythm Management590,000,000USD0000885725-25-000041
    Q2 2025Quarterly · 2025-06-30ProductGlobal Cardiology Reporting Unit — Electrophysiology EP840,000,000USD0000885725-25-000041
    Q2 2025Quarterly · 2025-06-30ProductGlobal Cardiology Reporting Unit — Watchman486,000,000USD0000885725-25-000041
    Q2 2025Quarterly · 2025-06-30ProductGlobal Endoscopy Endo Reporting Unit737,000,000USD0000885725-25-000041
    Q2 2025Quarterly · 2025-06-30ProductGlobal Neuromodulation Nm Reporting Unit303,000,000USD0000885725-25-000041
    Q2 2025Quarterly · 2025-06-30ProductGlobal Peripheral Interventions Pi Reporting Unit698,000,000USD0000885725-25-000041
    Q2 2025Quarterly · 2025-06-30ProductGlobal Urologyand Pelvic Health Reporting Unit676,000,000USD0000885725-25-000041
    Q2 2025Quarterly · 2025-06-30ProductInterventional Cardiology Therapies731,000,000USD0000885725-25-000041
    Q2 2025Quarterly · 2025-06-30SegmentCardiovascular3,345,000,000USD0000885725-25-000041
    Q2 2025Quarterly · 2025-06-30SegmentMedsurg1,716,000,000USD0000885725-25-000041
    Q1 2025Quarterly · 2025-03-31GeographyInternational1,702,000,000USD0000885725-26-000033
    Q1 2025Quarterly · 2025-03-31GeographyUnited States2,960,000,000USD0000885725-26-000033
    Q1 2025Quarterly · 2025-03-31ProductCardiac Rhythm Management578,000,000USD0000885725-26-000033
    Q1 2025Quarterly · 2025-03-31ProductElectrophysiology EP730,000,000USD0000885725-26-000033
    Q1 2025Quarterly · 2025-03-31ProductGlobal Endoscopy Endo Reporting Unit673,000,000USD0000885725-26-000033
    Q1 2025Quarterly · 2025-03-31ProductGlobal Neuromodulation Nm Reporting Unit271,000,000USD0000885725-26-000033
    Q1 2025Quarterly · 2025-03-31ProductGlobal Urologyand Pelvic Health Reporting Unit633,000,000USD0000885725-26-000033
    Q1 2025Quarterly · 2025-03-31ProductInterventional Cardiology Therapies1,124,000,000USD0000885725-26-000033
    Q1 2025Quarterly · 2025-03-31ProductInterventional Oncology And Embolization228,000,000USD0000885725-26-000033
    Q1 2025Quarterly · 2025-03-31ProductWatchman425,000,000USD0000885725-26-000033
    Q1 2025Quarterly · 2025-03-31SegmentCardiovascular3,085,000,000USD0000885725-26-000033
    Q1 2025Quarterly · 2025-03-31SegmentMedsurg1,577,000,000USD0000885725-26-000033
    Q4 2024Quarterly · 2024-12-31SegmentCardiovascular2,942,000,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31SegmentMedsurg1,619,000,000USDLegacy provider
    FY 2024Yearly · 2024-12-31ProductGlobal Cardiology Reporting Unit — Cardiac Rhythm Management2,279,000,000USD0000885725-25-000011
    FY 2024Yearly · 2024-12-31ProductGlobal Cardiology Reporting Unit — Electrophysiology EP1,904,000,000USD0000885725-25-000011
    FY 2024Yearly · 2024-12-31ProductGlobal Cardiology Reporting Unit — Watchman1,516,000,000USD0000885725-25-000011
    FY 2024Yearly · 2024-12-31ProductGlobal Endoscopy Endo Reporting Unit2,687,000,000USD0000885725-25-000011
    FY 2024Yearly · 2024-12-31ProductGlobal Neuromodulation Nm Reporting Unit1,106,000,000USD0000885725-25-000011
    FY 2024Yearly · 2024-12-31ProductGlobal Peripheral Interventions Pi Reporting Unit2,410,000,000USD0000885725-25-000011
    FY 2024Yearly · 2024-12-31ProductGlobal Urologyand Pelvic Health Reporting Unit2,200,000,000USD0000885725-25-000011
    FY 2024Yearly · 2024-12-31ProductInterventional Cardiology Therapies2,645,000,000USD0000885725-25-000011
    FY 2024Yearly · 2024-12-31ProductOther0USD0000885725-25-000011
    FY 2024Yearly · 2024-12-31SegmentCardiovascular10,755,000,000USD0000885725-26-000010
    FY 2024Yearly · 2024-12-31SegmentMedsurg5,993,000,000USD0000885725-26-000010
    Q3 2024Quarterly · 2024-09-30ProductGlobal Cardiology Reporting Unit — Cardiac Rhythm Management561,000,000USD0000885725-25-000050
    Q3 2024Quarterly · 2024-09-30ProductGlobal Cardiology Reporting Unit — Electrophysiology EP527,000,000USD0000885725-25-000050
    Q3 2024Quarterly · 2024-09-30ProductGlobal Cardiology Reporting Unit — Watchman380,000,000USD0000885725-25-000050
    Q3 2024Quarterly · 2024-09-30ProductGlobal Endoscopy Endo Reporting Unit678,000,000USD0000885725-25-000050
    Q3 2024Quarterly · 2024-09-30ProductGlobal Neuromodulation Nm Reporting Unit268,000,000USD0000885725-25-000050
    Q3 2024Quarterly · 2024-09-30ProductGlobal Peripheral Interventions Pi Reporting Unit602,000,000USD0000885725-25-000050
    Q3 2024Quarterly · 2024-09-30ProductGlobal Urologyand Pelvic Health Reporting Unit532,000,000USD0000885725-25-000050
    Q3 2024Quarterly · 2024-09-30ProductInterventional Cardiology Therapies661,000,000USD0000885725-25-000050
    Q3 2024Quarterly · 2024-09-30SegmentCardiovascular2,731,000,000USD0000885725-25-000050
    Q3 2024Quarterly · 2024-09-30SegmentMedsurg1,479,000,000USD0000885725-25-000050
    FY 2023Yearly · 2023-12-31ProductGlobal Cardiology Reporting Unit — Cardiac Rhythm Management2,218,000,000USD0000885725-25-000011
    FY 2023Yearly · 2023-12-31ProductGlobal Cardiology Reporting Unit — Electrophysiology EP800,000,000USD0000885725-25-000011
    FY 2023Yearly · 2023-12-31ProductGlobal Cardiology Reporting Unit — Watchman1,274,000,000USD0000885725-25-000011
    FY 2023Yearly · 2023-12-31ProductGlobal Endoscopy Endo Reporting Unit2,482,000,000USD0000885725-25-000011
    FY 2023Yearly · 2023-12-31ProductGlobal Neuromodulation Nm Reporting Unit976,000,000USD0000885725-25-000011
    FY 2023Yearly · 2023-12-31ProductGlobal Peripheral Interventions Pi Reporting Unit2,110,000,000USD0000885725-25-000011
    FY 2023Yearly · 2023-12-31ProductGlobal Urologyand Pelvic Health Reporting Unit1,964,000,000USD0000885725-25-000011
    FY 2023Yearly · 2023-12-31ProductInterventional Cardiology Therapies2,417,000,000USD0000885725-25-000011
    FY 2023Yearly · 2023-12-31ProductOther0USD0000885725-25-000011

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.